Following the accepted concept that the growth of solid tumors is dependent on their ability to elicit the development of new blood vessels into the tumor mass, there has been an increasing focus on targeting tumor vasculature. The angiogenic potential of the endothelial cell is carefully balanced between positive and negative regulation. Tumors have the potential to up-regulate or down-regulate these controls, producing an environment in which new blood formation occurs, thereby supporting tumor growth. Angiogenic factors include VEGF, fibroblast growth factor (FGF)-α and FGF-β, endothelial growth factor, tumor necrosis factor-α, and integrins.2 On the other hand, angiostatic factors include angiostatin, endostatin, transforming growth factor-β, tissue inhibitors of metalloproteinases, 2-methoxyestradiol, and squalamine.2–3 Indeed, antiangiogenic agents offer a potential for the treatment of cancers, but emerging data suggest that there may be limits to their use as monotherapy in patients with advanced malignancies. Therefore, the further accumulation of other markers of angiogenesis or other antiangiogenic molecules in malignant tumors, including lung cancers, are needed for future novel strategies.